Member access

4-Traders Homepage  >  Shares  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.It is also a leader in in-vitro... 
Surperformance© rating of Roche Holding Ltd.
Trading Rating : Investor Rating :
More about the company
Financials ( CHF)
Sales 2014 47 195 M
EBIT 2014 17 546 M
Net income 2014 11 815 M
Debt 2014 6 199 M
Yield 2014 2,95%
Sales 2015 49 537 M
EBIT 2015 18 812 M
Net income 2015 12 871 M
Finance 2015 888 M
Yield 2015 3,18%
PER 2014 20,02
PER 2015 18,23
EV / Sales 2014 5,19x
EV / Sales 2015 4,80x
Capitalization 238 563 M
More Financials
Latest news on ROCHE HOLDING LTD.
1d ago Roche to spend $3.2 billion on towering Basel base
1d agoDJRoche to Spend CHF3 Billion in Research Center, Basel Headquarters
7d ago ROCHE : Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® an..
7d ago New breast cancer drugs boost sales at Roche
10/15 ROCHE : FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulm..
10/13DJRoche Holding 3Q 2014 -- Forecast
10/08 ROCHE : FDA Grants Priority Review for Genentech’s Lucentis in Diabetic Re..
10/08 NOVARTIS : Shareholder group critical as Roche and Novartis chiefs top Swiss pay..
09/29 ROCHE : Genentech :’s Investigational Combination of Cobimetinib Plus Zelb..
09/28 ROCHE : Genentech :’s Perjeta Regimen Extended the Lives of People With an..
09/24 Adaptimmune raises $104 million to develop immune-system cancer drugs
09/17 For Roche CEO, celebrating failure is key to success
More news
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes